Dr. Stinchcombe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 Manning Dr
Chapel Hill, NC 27514Phone+1 919-966-4996Fax+1 919-843-5515
Education & Training
- University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1998 - 2001
- University of MichiganResidency, Internal Medicine, 1995 - 1998
- University of Virginia School of MedicineClass of 1995
Certifications & Licensure
- NC State Medical License 1998 - 2024
- MI State Medical License 1995 - 1998
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2006 Jan 01
- Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer Start of enrollment: 2005 May 01
- Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC Start of enrollment: 2006 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Combining Response and Toxicity Data to Implement Project Optimus.Robert G Maki, Thomas E Stinchcombe, Gary K Schwartz, Gini F Fleming, Alexia E Iasonos
Journal of Clinical Oncology. 2024-12-10 - Lung Cancer Screening and Early Detection Terminology: Time to Sing From the Same Song Sheet.Betty C Tong, Thomas E Stinchcombe
Journal of Thoracic Oncology. 2024-12-01 - Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance.Apar K Ganti, Briant Fruth, Andreas Rimner, Saiama Waqar, Michael D Mix
Cancer. 2024-11-24
Press Mentions
- Bevacizumab-Erlotinib Combo Falls Short in EGFR-Mutant Advanced NSCLCAugust 12th, 2019
- Considerations in the Management of ALK+ NSCLCAugust 7th, 2019
- Targeted Therapy for ALK+ NSCLCJuly 31st, 2019
- Join now to see all
Grant Support
- Clinical Trial: Phase I Trial Of Abraxane In Combination With Gemcitabine In SolNational Center For Research Resources2008
- Clinical Trial: Cisplatin/Etoposide Or Carboplatin/Pemetrexed In Patients With SNational Center For Research Resources2008
- Phase I Trial Of Abraxane In Combination With Gemcitabine In Solid TumorsNational Center For Research Resources2007
- Lccc 0412: Phase I Carboplatin And Abraxane In Patients With Solid TumorsNational Center For Research Resources2006–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: